Listed clinical trials group Hvivo said the first half of 2024 was “exceptionally strong” with record revenues and margins.
Earnings before interest, tax, depreciation and amortisation were £8.7 million, almost 67 per cent higher than in 2024, while Ebitda margins were 24.5 per cent. Basic adjusted earnings per share were 30.6 per cent higher at 0.81 pence. The company’s state of the art facility in Canary Wharf is now fully operational, Hvivo said, providing a foundation for new revenue streams with the completion of the fit-out of the CL-3 laboratory there. The company said there was interest in new challenge models, with potential revenue streams of around £40 million.
The group is targeting revenue of £100 million by 2028, with growth underpinned by the increased capacity of its facilities and a strong cash position.